产品说明书
(±)-Clopidogrel bisulfate
 |
同义名 : | - |
| CAS号 : | 135046-48-9 | |
| 货号 : | A262835 | |
| 分子式 : | C16H18ClNO6S2 | |
| 纯度 : | 98% | |
| 分子量 : | 419.9 | |
| MDL号 : | MFCD05865229 | |
| 存储条件： |
粉末 Inert atmosphere,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Clopidogrel is an inhibitor of platelet aggregation that is used to decrease the risk of myocardial infarction and stroke in patients known to have atherosclerosis. Clopidogrel has been linked to rare instances of idiosyncratic, clinically apparent acute liver injury. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02792712 | Acute Coronary Syndrome | Phase 4 | Unknown | January 2018 | Taiwan ... 展开 >> Teipei Veterans General Hospital Recruiting Taipei, Taiwan, 112 Contact: Tao-Cheng Wu, MD, PhD +886-2-28712121 ext 3655 dcwu@vghtpe.gov.tw Principal Investigator: Tao-Cheng Wu, MD, PhD 收起 << |
| NCT00620802 | Healthy | Phase 1 | Completed | - | United States, Kansas ... 展开 >> Quintiles Phase I Services Overland Park, Kansas, United States, 66211 收起 << |
| NCT01482117 | Interaction | Not Applicable | Completed | - | - |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.38mL 0.48mL 0.24mL |
11.91mL 2.38mL 1.19mL |
23.82mL 4.76mL 2.38mL |
| 参考文献 |
|---|